Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

NCT00447226 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class

Stopped The study had failed to meet the primary objective of tumor response rate at 12 weeks from first dose.

Conditions

Interventions

Sponsor

GlaxoSmithKline